



EXECUTIVE OFFICE OF THE PRESIDENT
OFFICE OF MANAGEMENT AND BUDGET
WASHINGTON, D.C. 20503

October 14, 2022

Statement from OMB Director Shalanda Young

**Budgetary Impact Analysis for Executive Order Entitled
“Lowering Prescription Drug Costs for Americans”**

This executive order directs the Secretary of the Department of Health and Human Services to report back in 90 days with a plan for administrative actions that will lower drug costs for Americans. Implementing this executive order would have de minimis impact on costs and revenues to the Federal Government. The benefits of this executive order include promoting lower drug costs and greater access to treatments for beneficiaries of Medicare and Medicaid. Implementing this executive order would have de minimis impact on mandatory and discretionary obligations and outlays, as well as on revenues to the Federal Government, in the 5-year fiscal period beginning in fiscal year 2023. The agencies anticipated to be impacted by this executive order include the Department of Health and Human Services.